| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4367364 | Binding | Inhibition of human VEGFR3 at 1 uM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]ATP relative to control | Homo sapiens | 2 | ALA4364295 | single protein format | Scientific Literature | |
| 2. | ALA4367392 | ADME | AUC in Sprague-Dawley rat assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po by LC/MS/MS analysis | Rattus norvegicus | 4 | ALA4364295 | organism-based format | Scientific Literature | |
| 3. | ALA4367393 | ADME | Drug uptake in po dosed Sprague-Dawley rat systemic circulation by LC/MS/MS analysis | Rattus norvegicus | 5 | ALA4364295 | organism-based format | Scientific Literature | |
| 4. | ALA4367394 | ADME | Prodrug conversion in Sprague-Dawley rat hepatic portal vein assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol formation | Rattus norvegicus | 2 | ALA4364295 | tissue-based format | Scientific Literature | |
| 5. | ALA4367399 | Binding | Inhibition of human ERG (1159 residues) expressed in CHOK1 cells at -80 mV holding potential measured after 5 mins by QPatch electrophysiology method | Homo sapiens | 3 | ALA4364295 | cell-based format | Scientific Literature | |
| 6. | ALA4367400 | ADME | Inhibition of CYP3A4 (unknown origin) | Homo sapiens | 1 | ALA4364295 | single protein format | Scientific Literature | |
| 7. | ALA4367401 | ADME | Cmax in Sprague-Dawley rat assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po by LC/MS/MS analysis | Rattus norvegicus | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 8. | ALA4367402 | ADME | AUC in Sprague-Dawley rat assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po by LC/MS/MS analysis | Rattus norvegicus | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 9. | ALA4367403 | ADME | Clearance in Sprague-Dawley rat assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po or 1.1 mg/kg, iv by LC/MS/MS analysis | Rattus norvegicus | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 10. | ALA4367404 | ADME | Volume of distribution at steady state in Sprague-Dawley rat assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po or 1.1 mg/kg, iv by LC/MS/MS analysis | Rattus norvegicus | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 11. | ALA4367405 | ADME | Terminal half life in Sprague-Dawley rat assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po or 1.1 mg/kg, iv by LC/MS/MS analysis | Rattus norvegicus | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 12. | ALA4367406 | ADME | Oral bioavailability in Sprague-Dawley rat assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg by LC/MS/MS analysis | Rattus norvegicus | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 13. | ALA4367407 | ADME | Cmax in Beagle dog assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po by LC/MS/MS analysis | Canis lupus familiaris | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 14. | ALA4367408 | ADME | AUC in Beagle dog assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po by LC/MS/MS analysis | Canis lupus familiaris | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 15. | ALA4367409 | ADME | Clearance in Beagle dog assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po or 0.9 mg/kg, iv by LC/MS/MS analysis | Canis lupus familiaris | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 16. | ALA4367410 | ADME | Volume of distribution at steady state in Beagle dog assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po or 0.9 mg/kg, iv by LC/MS/MS analysis | Canis lupus familiaris | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 17. | ALA4367411 | ADME | Terminal half life in Beagle dog assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg, po or 0.9 mg/kg, iv by LC/MS/MS analysis | Canis lupus familiaris | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 18. | ALA4367412 | ADME | Oral bioavailability in Beagle dog assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 2 mg/kg by LC/MS/MS analysis | Canis lupus familiaris | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 19. | ALA4367413 | ADME | Cmax in Gottingen minipig assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 1 mg/kg, po by LC/MS/MS analysis | Sus scrofa | 1 | ALA4364295 | organism-based format | Scientific Literature | |
| 20. | ALA4367414 | ADME | AUC in Gottingen minipig assessed as 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol level at 1 mg/kg, po by LC/MS/MS analysis | Sus scrofa | 1 | ALA4364295 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!